Molecular Targets for Pharmacotherapy of Head and Neck Squamous Cell Carcinomas

View Full Paper

Ask AI

Bookmark

Main finding is that traditional chemotherapy offers limited efficacy due to toxicity and tumor resistance in head and neck squamous cell carcinomas.
Immunotherapy, particularly targeting PD-L1, has improved survival rates, especially in patients with high expression of this protein.
Current approaches include chemotherapy, immunotherapy, and innovative targeted therapies like PARP1 and CDK inhibitors for HNSCC.
The review emphasizes future directions such as combination therapies and precision medicine to enhance treatment effectiveness.

Discussion

No takes yet. Share an insight, caveat, or question.

Review summarizes treatment options in head and neck squamous cell carcinomas, highlighting immunotherapy and targeted therapies' potential benefits.

Sarna et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Review summarizes treatment options in head and neck squamous cell carcinomas, highlighting immunotherapy and targeted therapies' potential benefits.